Qube Research & Technologies (QRT)’s Karyopharm Therapeutics KPTI Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-4,135	Closed	-$51.5K	–	3665
2024 Q3	$51.5K	Sell	4,135 -2,963	-42%	-$36.8K	﹤0.01%	2855
2024 Q2	$92.4K	Buy	+7,098	New	+$118K	﹤0.01%	2620
2023 Q3	–	Sell	-46,871	Closed	-$1.26M	–	4226
2023 Q2	$1.26M	Buy	+46,871	New	+$2.02M	﹤0.01%	1214
2023 Q1	–	Sell	-34,919	Closed	-$1.78M	–	2809
2022 Q4	$1.78M	Buy	+34,919	New	+$2.42M	0.01%	988
2022 Q3	–	Sell	-16,200	Closed	-$1.1M	–	2777
2022 Q2	$1.1M	Buy	+16,200	New	+$1.49M	0.01%	1062
2021 Q2	–	Sell	-9,763	Closed	-$1.54M	–	2548
2021 Q1	$1.54M	Buy	9,763 +3,674	+60%	+$774K	0.02%	696
2020 Q4	$1.41M	Buy	6,089 +3,927	+182%	+$910K	0.02%	756
2020 Q3	$473K	Buy	+2,162	New	+$529K	0.01%	1060

Other funds holding KPTI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Qube Research & Technologies (QRT)'s KPTI Position: Q4 2024 in Review

Qube Research & Technologies (QRT) sold out of Karyopharm Therapeutics (KPTI) in Q4 2024, closing a stake of 4,135 shares — an estimated $51.5K sold.

Qube Research & Technologies (QRT) first reported a position in KPTI in Q3 2020 and held it in 8 quarters. The position peaked at $1.78M in Q4 2022. 87 funds tracked by Wall St. Rank hold KPTI as of Q4 2024.

Qube Research & Technologies (QRT) reported no remaining Karyopharm Therapeutics position as of Q4 2024 after selling out during the quarter.
Qube Research & Technologies (QRT) sold 4,135 Karyopharm Therapeutics shares in Q4 2024, an estimated $51.5K.
Qube Research & Technologies (QRT) first reported a position in Karyopharm Therapeutics in Q3 2020 and held it in 8 quarters.
Qube Research & Technologies (QRT)'s Karyopharm Therapeutics position peaked at $1.78M in Q4 2022.
87 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2024.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q4 2024, filed 14 Feb 2025.